Developer docs
API playgroundTry for free, no card

Search company profiles

Arabio

Full company profile

uuid000wy5m

Namestring
Arabio
Legal namestring
Arab Company for Pharmaceutical Products
Websiteurl
arabio.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Arabio (legal name: Arab Company for Pharmaceutical Products) is a Saudi Arabian biopharmaceutical company founded in 2005 and headquartered in Riyadh, with a 10,000 m² cGMP-compliant manufacturing facility in Makkah Industrial Zone that has been operational since 2011. It is the first biotech manufacturing site in the GCC region purpose-built for vaccines, producing 10 vaccines that form part of Saudi Arabia's mandatory Expanded Program on Immunization (EPI), including hexavalent (HEXAXIM), pentavalent (PENTAXIM, ARAPENTA), meningococcal conjugate (MENACTRA), quadrivalent influenza (VAXIGRIPTETRA), hepatitis B (EUVAX), and tetanus/diphtheria (STABLIX, TEDALIX) products. The company also toll-manufactures biologics such as AbbVie's Humira and Janssen's biological products, and distributes a broader portfolio including COVID-19, pneumococcal, MMR, RSV, varicella, rotavirus, HPV, and MMRV vaccines.

Arabio makes money primarily through two B2B/B2G channels: (1) sale and supply of locally manufactured and licensed vaccines to government health ministries (notably the Saudi MoH for the EPI schedule, GCC health ministries via GSK partnerships, and the Saudi MoD for adult vaccination) and to private healthcare providers across MENA, and (2) contract/toll manufacturing fees and licensing royalties from global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, Janssen, BioFarma, and InterVax. The company is majority owned (65.21%) by Tamer Group, with other Saudi shareholders including ReAya Holding International and Khalid Juffali Co Ltd, and operates with a headcount of 101–250 employees across offices in Riyadh, Makkah, and Dubai (via Alphamed).

In 2024, Arabio signed two strategically significant MOUs: a tripartite agreement with Lifera (PIF-owned) and Sanofi to locally manufacture seven mandatory-schedule vaccines with regional export potential, and an MoU with the Saudi Ministry of Defense to establish a Center of Excellence in Vaccines and an Adult Vaccination Program. Its go-to-market combines direct sales to government and healthcare provider accounts with regional distribution through Tamer Group's MENA network and dedicated distributors such as Alphamed in the UAE, supported by validated cold-chain logistics.

Short descriptiontext

Arabio is a Saudi biopharmaceutical company and the first vaccine manufacturer in the GCC, operating a 10,000 m² cGMP facility in Makkah. It supplies 10 vaccines on Saudi Arabia's mandatory immunization schedule, toll-manufactures biologics for global pharma partners, and distributes across 22 MENA countries via Tamer Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRiyadh, Saudi Arabia
HQ citystring
Riyadh
HQ countrystring
Saudi Arabia
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine manufacturing, biopharmaceutical products, biological products, contract manufacturing, cold chain distribution
Industry4 codes
PRIMARYHLAIAEAJ
Vaccine Manufacturing & Fill-Finish
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAJAG
Vaccines & Cold-Chain Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccine Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Manufacturing and Supply
TypeOne Time License
Description

Arabio manufactures and supplies vaccines to the Saudi market and MENA region through partnerships with global pharmaceutical companies. Revenue comes from contract manufacturing fees and product sales of vaccines including HEXAXIM, MENACTRA, VAXIGRIPTETRA, PENTAXIM, and others that are part of the mandatory immunization schedule.

arabio.com
2Distribution and Commercialization
TypeLicensing Royalties
Description

Partnership with Sanofi for local manufacturing where Lifera acts as contract manufacturer to Sanofi. Arabio and Tamer Group leverage local and regional distribution strength to supply vaccines and pharmaceutical products to the Saudi market.

3Toll Manufacturing
TypeProfessional Services
Description

Arabio acts as toll manufacturer for biological products, including AbbVie's Humira and other drugs, and Janssen's biological products, where the partner provides the product and Arabio handles local manufacturing.

arabio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arabio manufactures and supplies human vaccines and biological products from its 10,000 m2 cGMP-compliant facility in Makkah, Saudi Arabia. The company supplies 10 vaccines that are part of the mandatory Expanded Program on Immunization (EPI) in Saudi Arabia and operates as a contract/toll manufacturer for global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, and Janssen.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Market leader in Saudi Arabia supplying 10 vaccines part of mandatory immunization schedule
+2 more records
Product overview1 text field

Arabio is a biopharmaceutical company specializing in human vaccines and biological products. The company operates as a contract manufacturer and distributor, providing 10 vaccines that form part of the mandatory vaccination schedule (EPI) in Saudi Arabia. The product portfolio includes hexavalent vaccines (HEXAXIM), pentavalent vaccines (PENTAXIM, ARAPENTA), meningococcal conjugate vaccines (MENACTRA), quadrivalent influenza vaccines (VAXIGRIPTETRA), hepatitis B vaccines (EUVAX 10/20 MCG), tetanus vaccines (STABLIX, TEDALIX), and various other vaccines including COVID-19, pneumococcal, MMR, RSV, varicella, rota, and HPV vaccines. Arabio also manufactures biological products including Humira under toll manufacturing agreements. The company supplies vaccines across the MENA region through partnerships with global pharmaceutical companies including Sanofi, GSK Vaccines, Novartis, Janssen, and BioFarma, with distribution through Alphamed in the UAE.

Product and service18 records
1HEXAXIM
CategoryVaccine
Description

Hexavalent vaccine combining pertussis (2-component), inactivated poliomyelitis and hepatitis B vaccine (adsorbed), and Haemophilus influenzae type b conjugate vaccine (Tetanus Toxoid Conjugate). Used in pediatric mandatory immunization programs in Saudi Arabia.

2MENACTRA
CategoryVaccine
Description

Quadrivalent meningococcal conjugate vaccine (MCV4) providing protection against Groups A, C, Y and W strains, conjugated with diphtheria toxoid. Used in mandatory immunization programs.

3VAXIGRIPTETRA
CategoryVaccine
Description

Inactivated quadrivalent influenza vaccine (QIV) containing two A-strains (A/H1N1 and A/H3N2) and two B-strains (B Victoria and B Yamagata). Used in influenza prevention programs.

4PENTAXIM
CategoryVaccine
Description

Pentavalent vaccine combining pertussis (2-component), inactivated poliomyelitis, and Haemophilus influenzae type b conjugate vaccine (Tetanus Toxoid Conjugate). Used in mandatory immunization programs.

5ARAPENTA
CategoryVaccine
Description

Pentavalent vaccine containing diphtheria and tetanus toxoids, inactivated pertussis organisms, highly purified hepatitis B surface antigen (HBsAg), and Hib component as a bacterial subunit vaccine.

6EUVAX 10 MCG (PEDIA)
CategoryVaccine
Description

Pediatric hepatitis B vaccine containing highly purified, non-infectious particles of hepatitis B surface antigen for protection against hepatitis B infection.

7EUVAX 20 MCG (ADULT)
CategoryVaccine
Description

Adult hepatitis B vaccine containing highly purified, non-infectious particles of hepatitis B surface antigen for protection against hepatitis B infection.

8STABLIX
CategoryVaccine
Description

Purified tetanus toxoid vaccine used for tetanus prevention and post-exposure prophylaxis for recent wounds that may have been contaminated with tetanus spores.

9TEDALIX
CategoryVaccine
Description

Combined tetanus toxoid and diphtheria toxoid vaccine for adults.

10COVID-19 Vaccines
CategoryVaccine
Description

Vaccines targeting COVID-19 disease prevention, distributed in MENA markets.

11Pneumococcal Vaccines
CategoryVaccine
Description

Vaccines providing protection against pneumococcal disease.

12MMR Vaccines
CategoryVaccine
Description

Measles, mumps, and rubella combination vaccines.

13RSV Vaccines
CategoryVaccine
Description

Vaccines targeting respiratory syncytial virus (RSV).

14Varicella Vaccines
CategoryVaccine
Description

Vaccines providing protection against chickenpox (varicella).

15Rota Vaccines
CategoryVaccine
Description

Rotavirus vaccines for protection against rotavirus gastroenteritis.

16HPV Vaccines
CategoryVaccine
Description

Human papillomavirus vaccines for prevention of HPV-related cancers.

17MMRV Vaccines
CategoryVaccine
Description

Combined measles, mumps, rubella, and varicella vaccines.

18Humira
CategoryBiological Product
Description

Biologic medication manufactured locally under toll manufacturing agreement with AbbVie for the Saudi market.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1General Directorate of Health Services at the Ministry of Defense (Saudi Arabia)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-25
Description

Arabio signed MoU with the Ministry of Defense's Health Services to establish a Center of Excellence in Vaccines. The partnership includes implementation of Adult Vaccination Program, development of new methodologies for healthcare delivery projects, training and educational courses for healthcare practitioners, and awareness programs on immunization.

arabio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-06
Description

Arabio partnered with Sanofi and Lifera (PIF-owned biopharma company) to manufacture and supply vaccines in Saudi Arabia. Sanofi will share biotechnological expertise to initially manufacture seven vaccines part of the mandatory immunization schedule, with potential for regional export market. Lifera will be contract manufacturer to Sanofi through state-of-the-art manufacturing facilities, while Arabio leverages Tamer Group's distribution strength.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-06
Description

Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF), partnered with Sanofi and Arabio to increase local vaccine production. Lifera will serve as contract manufacturer to Sanofi through manufacturing facilities, while collaborating with Arabio for local and regional distribution of vaccines and pharmaceutical products in Saudi Arabia.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-03-20
Description

Tripartite manufacturing agreement between Arabio, GSAL and GSK Vaccines established long-term alliance. Arabio appointed as contract manufacturer for filling and packaging of selected liquid vaccines in prefilled syringes and vials for GCC countries. All GSK Vaccines for Saudi Arabia's Universal Vaccination Program are manufactured locally either by GSAL or Arabio.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2012-01-10
Description

Arabio appointed Alphamed as its sales and distribution partner in the United Arab Emirates (UAE). Alphamed handles distribution of Arabio's vaccines in the UAE market.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2010-09-11
Description

Novartis partnered with Arabio for Middle East vaccine production. Technical assistance from Novartis' Vaccines and Diagnostics divisions for Arabio's manufacturing facility in Makkah, with technology transfer agreement enabling manufacture of Menveo meningitis vaccine, Agrippal flu vaccine, and Quinvaxem pentavalent vaccine.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Indian vaccine manufacturer (Bulls Group/NDDB-affiliated) supplying pediatric and travel vaccines to emerging markets including MENA. Comparable as a regional-to-emerging market vaccine producer with similar WHO-prequalification positioning.

TypeBroad incumbent
Description

Saudi-listed pharmaceutical manufacturer with a diversified portfolio across generics and select biologics. Comparable as a domestic Saudi pharmaceutical peer serving similar government and institutional channels.

3Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccines leader and Arabio's primary technology transfer partner. Comparable as a vaccine originator whose products Arabio manufactures under license, defining the competitive benchmark for capability and pipeline depth.

4Julphar (Gulf Pharmaceutical Industries)
TypeBroad incumbent
Description

UAE-based pharmaceutical manufacturer with a broad generics and biologics portfolio. While not vaccine-specialized, Julphar is a comparable regional pharmaceutical manufacturer competing for GCC government and institutional contracts.

TypeRegional player
Description

Indonesian state-owned vaccine manufacturer and Arabio's licensing partner for WHO-prequalified vaccines in MENA. Comparable as a regional vaccine producer leveraging technology transfer partnerships for emerging market expansion.

6Biological E
TypeEmerging player
Description

Indian vaccine and biologics manufacturer with WHO-prequalified products supplying emerging markets. Comparable as a contract manufacturer expanding into MENA with similar technology transfer models to Arabio.

TypeRegional player
Description

Egyptian state-affiliated vaccine and biological products manufacturer and a 2.84% shareholder of Arabio. Vacsera is a comparable regional vaccine producer with overlapping MENA distribution footprint and product portfolio.

TypeBroad incumbent
Description

World's largest vaccine manufacturer by doses, supplying WHO-prequalified vaccines globally including MENA EPI programs. Comparable as a low-cost, high-volume vaccine producer competing on price in regional tenders.

TypeDirect peer
Description

Saudi Arabia-based biopharmaceutical company wholly owned by the Public Investment Fund (PIF). Lifera is positioned as Sanofi's contract manufacturer in the 2024 trilateral MOU with Arabio, making it the most directly comparable peer in local vaccine manufacturing.

TypeBroad incumbent
Description

Global vaccines leader with a tripartite manufacturing agreement with Arabio and GSAL. Comparable as both a partner and a benchmark global vaccine originator competing in the same MENA EPI markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arabio

Vaccine Manufacturingarabio.com

Arabio is a Saudi biopharmaceutical company and the first vaccine manufacturer in the GCC, operating a 10,000 m² cGMP facility in Makkah. It supplies 10 vaccines on Saudi Arabia's mandatory immunization schedule, toll-manufactures biologics for global pharma partners, and distributes across 22 MENA countries via Tamer Group.

What Arabio does

Arabio (legal name: Arab Company for Pharmaceutical Products) is a Saudi Arabian biopharmaceutical company founded in 2005 and headquartered in Riyadh, with a 10,000 m² cGMP-compliant manufacturing facility in Makkah Industrial Zone that has been operational since 2011. It is the first biotech manufacturing site in the GCC region purpose-built for vaccines, producing 10 vaccines that form part of Saudi Arabia's mandatory Expanded Program on Immunization (EPI), including hexavalent (HEXAXIM), pentavalent (PENTAXIM, ARAPENTA), meningococcal conjugate (MENACTRA), quadrivalent influenza (VAXIGRIPTETRA), hepatitis B (EUVAX), and tetanus/diphtheria (STABLIX, TEDALIX) products. The company also toll-manufactures biologics such as AbbVie's Humira and Janssen's biological products, and distributes a broader portfolio including COVID-19, pneumococcal, MMR, RSV, varicella, rotavirus, HPV, and MMRV vaccines.

Arabio makes money primarily through two B2B/B2G channels: (1) sale and supply of locally manufactured and licensed vaccines to government health ministries (notably the Saudi MoH for the EPI schedule, GCC health ministries via GSK partnerships, and the Saudi MoD for adult vaccination) and to private healthcare providers across MENA, and (2) contract/toll manufacturing fees and licensing royalties from global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, Janssen, BioFarma, and InterVax. The company is majority owned (65.21%) by Tamer Group, with other Saudi shareholders including ReAya Holding International and Khalid Juffali Co Ltd, and operates with a headcount of 101–250 employees across offices in Riyadh, Makkah, and Dubai (via Alphamed).

In 2024, Arabio signed two strategically significant MOUs: a tripartite agreement with Lifera (PIF-owned) and Sanofi to locally manufacture seven mandatory-schedule vaccines with regional export potential, and an MoU with the Saudi Ministry of Defense to establish a Center of Excellence in Vaccines and an Adult Vaccination Program. Its go-to-market combines direct sales to government and healthcare provider accounts with regional distribution through Tamer Group's MENA network and dedicated distributors such as Alphamed in the UAE, supported by validated cold-chain logistics.

Arabio firmographics

Firmographics
Name
Arabio
Legal name
Arab Company for Pharmaceutical Products
Website
https://arabio.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Arabio is a Saudi biopharmaceutical company and the first vaccine manufacturer in the GCC, operating a 10,000 m² cGMP facility in Makkah. It supplies 10 vaccines on Saudi Arabia's mandatory immunization schedule, toll-manufactures biologics for global pharma partners, and distributes across 22 MENA countries via Tamer Group.
Ownership category
akta.pro rank

Arabio industry classification

Industry
Product category
Vaccine Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAJ
Vaccine Manufacturing & Fill-Finish
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAJAG
Vaccines & Cold-Chain Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution

Keywords

  • Vaccine manufacturing
  • Biopharmaceutical products
  • Biological products
  • Contract manufacturing
  • Cold chain distribution

Where Arabio is headquartered

Location

Headquarters

HQ city
Riyadh
HQ country
Saudi Arabia
HQ region
Middle East

Offices3 records

Markets served

Arabio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Infrastructure, Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Vaccine Manufacturing and Supply: Arabio manufactures and supplies vaccines to the Saudi market and MENA region through partnerships with global pharmaceutical companies. Revenue comes from contract manufacturing fees and product sales of vaccines including HEXAXIM, MENACTRA, VAXIGRIPTETRA, PENTAXIM, and others that are part of the mandatory immunization schedule.
  2. Distribution and Commercialization: Partnership with Sanofi for local manufacturing where Lifera acts as contract manufacturer to Sanofi. Arabio and Tamer Group leverage local and regional distribution strength to supply vaccines and pharmaceutical products to the Saudi market.
  3. Toll Manufacturing: Arabio acts as toll manufacturer for biological products, including AbbVie's Humira and other drugs, and Janssen's biological products, where the partner provides the product and Arabio handles local manufacturing.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Arabio product offering

Product offering

Core offering

Arabio manufactures and supplies human vaccines and biological products from its 10,000 m2 cGMP-compliant facility in Makkah, Saudi Arabia. The company supplies 10 vaccines that are part of the mandatory Expanded Program on Immunization (EPI) in Saudi Arabia and operates as a contract/toll manufacturer for global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, and Janssen.

Product overview

Arabio is a biopharmaceutical company specializing in human vaccines and biological products. The company operates as a contract manufacturer and distributor, providing 10 vaccines that form part of the mandatory vaccination schedule (EPI) in Saudi Arabia. The product portfolio includes hexavalent vaccines (HEXAXIM), pentavalent vaccines (PENTAXIM, ARAPENTA), meningococcal conjugate vaccines (MENACTRA), quadrivalent influenza vaccines (VAXIGRIPTETRA), hepatitis B vaccines (EUVAX 10/20 MCG), tetanus vaccines (STABLIX, TEDALIX), and various other vaccines including COVID-19, pneumococcal, MMR, RSV, varicella, rota, and HPV vaccines. Arabio also manufactures biological products including Humira under toll manufacturing agreements. The company supplies vaccines across the MENA region through partnerships with global pharmaceutical companies including Sanofi, GSK Vaccines, Novartis, Janssen, and BioFarma, with distribution through Alphamed in the UAE.

Differentiator

Problem solved

Functional benefit

Products and services

  • HEXAXIM Hexavalent vaccine combining pertussis (2-component), inactivated poliomyelitis and hepatitis B vaccine (adsorbed), and Haemophilus influenzae type b conjugate vaccine (Tetanus Toxoid Conjugate). Used in pediatric mandatory immunization programs in Saudi Arabia.
  • MENACTRA Quadrivalent meningococcal conjugate vaccine (MCV4) providing protection against Groups A, C, Y and W strains, conjugated with diphtheria toxoid. Used in mandatory immunization programs.
  • VAXIGRIPTETRA Inactivated quadrivalent influenza vaccine (QIV) containing two A-strains (A/H1N1 and A/H3N2) and two B-strains (B Victoria and B Yamagata). Used in influenza prevention programs.
  • PENTAXIM Pentavalent vaccine combining pertussis (2-component), inactivated poliomyelitis, and Haemophilus influenzae type b conjugate vaccine (Tetanus Toxoid Conjugate). Used in mandatory immunization programs.
  • ARAPENTA Pentavalent vaccine containing diphtheria and tetanus toxoids, inactivated pertussis organisms, highly purified hepatitis B surface antigen (HBsAg), and Hib component as a bacterial subunit vaccine.
  • EUVAX 10 MCG (PEDIA) Pediatric hepatitis B vaccine containing highly purified, non-infectious particles of hepatitis B surface antigen for protection against hepatitis B infection.
  • EUVAX 20 MCG (ADULT) Adult hepatitis B vaccine containing highly purified, non-infectious particles of hepatitis B surface antigen for protection against hepatitis B infection.
  • STABLIX Purified tetanus toxoid vaccine used for tetanus prevention and post-exposure prophylaxis for recent wounds that may have been contaminated with tetanus spores.
  • TEDALIX Combined tetanus toxoid and diphtheria toxoid vaccine for adults.
  • COVID-19 Vaccines Vaccines targeting COVID-19 disease prevention, distributed in MENA markets.
  • Pneumococcal Vaccines Vaccines providing protection against pneumococcal disease.
  • MMR Vaccines Measles, mumps, and rubella combination vaccines.
  • RSV Vaccines Vaccines targeting respiratory syncytial virus (RSV).
  • Varicella Vaccines Vaccines providing protection against chickenpox (varicella).
  • Rota Vaccines Rotavirus vaccines for protection against rotavirus gastroenteritis.
  • HPV Vaccines Human papillomavirus vaccines for prevention of HPV-related cancers.
  • MMRV Vaccines Combined measles, mumps, rubella, and varicella vaccines.
  • Humira Biologic medication manufactured locally under toll manufacturing agreement with AbbVie for the Saudi market.

Quantifiable outcome

  • Market leader in Saudi Arabia supplying 10 vaccines part of mandatory immunization schedule
  • +2 more outcomes

Companies that use Arabio

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Arabio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Arabio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • General Directorate of Health Services at the Ministry of Defense (Saudi Arabia)coreStrategic or Co-development Partner · 25 September 2024Arabio signed MoU with the Ministry of Defense's Health Services to establish a Center of Excellence in Vaccines. The partnership includes implementation of Adult Vaccination Program, development of new methodologies for healthcare delivery projects, training and educational courses for healthcare practitioners, and awareness programs on immunization.
  • SanoficoreStrategic or Co-development Partner · 6 July 2024Arabio partnered with Sanofi and Lifera (PIF-owned biopharma company) to manufacture and supply vaccines in Saudi Arabia. Sanofi will share biotechnological expertise to initially manufacture seven vaccines part of the mandatory immunization schedule, with potential for regional export market. Lifera will be contract manufacturer to Sanofi through state-of-the-art manufacturing facilities, while Arabio leverages Tamer Group's distribution strength.
  • LiferacoreStrategic or Co-development Partner · 6 July 2024Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF), partnered with Sanofi and Arabio to increase local vaccine production. Lifera will serve as contract manufacturer to Sanofi through manufacturing facilities, while collaborating with Arabio for local and regional distribution of vaccines and pharmaceutical products in Saudi Arabia.
  • GSK VaccinescoreTechnology or Integration · 20 March 2014Tripartite manufacturing agreement between Arabio, GSAL and GSK Vaccines established long-term alliance. Arabio appointed as contract manufacturer for filling and packaging of selected liquid vaccines in prefilled syringes and vials for GCC countries. All GSK Vaccines for Saudi Arabia's Universal Vaccination Program are manufactured locally either by GSAL or Arabio.
  • AlphamedminorChannel Partner/ Reseller/ Distributor · 10 January 2012Arabio appointed Alphamed as its sales and distribution partner in the United Arab Emirates (UAE). Alphamed handles distribution of Arabio's vaccines in the UAE market.
  • Novartis Vaccines & DiagnosticscoreTechnology or Integration · 11 September 2010Novartis partnered with Arabio for Middle East vaccine production. Technical assistance from Novartis' Vaccines and Diagnostics divisions for Arabio's manufacturing facility in Makkah, with technology transfer agreement enabling manufacture of Menveo meningitis vaccine, Agrippal flu vaccine, and Quinvaxem pentavalent vaccine.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Arabio competitors and assessment

Company assessment

Emerging players

  • Indian Immunologicals: Indian vaccine manufacturer (Bulls Group/NDDB-affiliated) supplying pediatric and travel vaccines to emerging markets including MENA. Comparable as a regional-to-emerging market vaccine producer with similar WHO-prequalification positioning.
  • Biological E: Indian vaccine and biologics manufacturer with WHO-prequalified products supplying emerging markets. Comparable as a contract manufacturer expanding into MENA with similar technology transfer models to Arabio.

Broad incumbents

  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi-listed pharmaceutical manufacturer with a diversified portfolio across generics and select biologics. Comparable as a domestic Saudi pharmaceutical peer serving similar government and institutional channels.
  • Sanofi Pasteur: Global vaccines leader and Arabio's primary technology transfer partner. Comparable as a vaccine originator whose products Arabio manufactures under license, defining the competitive benchmark for capability and pipeline depth.
  • Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with a broad generics and biologics portfolio. While not vaccine-specialized, Julphar is a comparable regional pharmaceutical manufacturer competing for GCC government and institutional contracts.
  • Serum Institute of India: World's largest vaccine manufacturer by doses, supplying WHO-prequalified vaccines globally including MENA EPI programs. Comparable as a low-cost, high-volume vaccine producer competing on price in regional tenders.
  • GSK Vaccines: Global vaccines leader with a tripartite manufacturing agreement with Arabio and GSAL. Comparable as both a partner and a benchmark global vaccine originator competing in the same MENA EPI markets.

Regional players

  • BioFarma: Indonesian state-owned vaccine manufacturer and Arabio's licensing partner for WHO-prequalified vaccines in MENA. Comparable as a regional vaccine producer leveraging technology transfer partnerships for emerging market expansion.
  • Vacsera (Egyptian Holding Company for Biological Products and Vaccines): Egyptian state-affiliated vaccine and biological products manufacturer and a 2.84% shareholder of Arabio. Vacsera is a comparable regional vaccine producer with overlapping MENA distribution footprint and product portfolio.

Direct peers

  • Lifera: Saudi Arabia-based biopharmaceutical company wholly owned by the Public Investment Fund (PIF). Lifera is positioned as Sanofi's contract manufacturer in the 2024 trilateral MOU with Arabio, making it the most directly comparable peer in local vaccine manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Arabio social profiles

Digital presence

Arabio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arabio leadership team

Management profile

Number of profiles

Profiles2 records

Arabio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arabio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arabio

What does Arabio do?

Arabio manufactures and supplies human vaccines and biological products from its 10,000 m2 cGMP-compliant facility in Makkah, Saudi Arabia. The company supplies 10 vaccines that are part of the mandatory Expanded Program on Immunization (EPI) in Saudi Arabia and operates as a contract/toll manufacturer for global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, and Janssen.

Is Arabio a public or private company?

Arabio is a private company. It is classified as family owned and is currently operating.

When was Arabio founded?

Arabio was founded in 2005. It employs 101 to 250 people.

Where is Arabio based?

Arabio is headquartered in Riyadh, Saudi Arabia, in the Middle East region.

How does Arabio make money?

Three revenue lines are on record. Vaccine Manufacturing and Supply is the primary driver. The others are distribution and Commercialization and toll Manufacturing.

Who are Arabio's main competitors?

Emerging players on record are Indian Immunologicals and Biological E. Broad incumbents are SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Sanofi Pasteur, Julphar (Gulf Pharmaceutical Industries), Serum Institute of India and GSK Vaccines. Regional players are BioFarma and Vacsera (Egyptian Holding Company for Biological Products and Vaccines). Lifera is listed as a direct peer.

Does Arabio have an API?

No public API is recorded for Arabio.

What industry is Arabio in?

Arabio's product category is Vaccine Manufacturing. Its primary akta.pro industry code is HLAIAEAJ, Vaccine Manufacturing & Fill-Finish, with a secondary code of HLAAAEAJ, Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
eyeofriyadh.comHimaya Makes Its Mark at the Umrah and Ziyarah Forum 2026, Bringing Health to Heart of the Pilgrim ExperienceAt the Umrah and Ziyarah Forum 2026 in Madinah, Sanofi and Arabio showcased the Himaya initiative and held a panel on pilgrim health preparedness. The discussion focused on meningococcal vaccination, with officials and industry leaders advocating for its implementation. The initiative aims to make vaccination accessible via the Sehhaty App, with one appointment securing five years of protection.ZawyaHimaya makes its mark at the Umrah and Ziyarah Forum 2026,bringing health to heart of the pilgrim experienceSanofi and Arabio introduced the Himaya initiative at the Umrah and Ziyarah Forum 2026 in Madinah, focusing on pilgrim health. The initiative promotes meningitis, flu, and COVID vaccines, with vaccination recommended at least ten days before travel. The forum gathered over 29,000 visitors from 165 countries.EIN PresswireHimaya Makes Its Mark at the Umrah and Ziyarah Forum 2026, Bringing Health to Heart of the Pilgrim ExperienceSanofi and Arabio showcased the Himaya initiative at the Umrah and Ziyarah Forum 2026 in Madinah, Saudi Arabia, focusing on pilgrim health preparedness. The initiative promotes meningitis, flu, and COVID vaccinations, with one appointment securing five years of protection. The forum highlighted over eight million Umrah performers in Q1 2025.PR NewswireLIFERA, SANOFI and ARABIO Sign MOU to Manufacture and Supply Vaccines in Saudi Arabia, Boosting Local Production with a New State-Of-The-Art Manufacturing FacilityLifera, Sanofi, and Arabio signed a Memorandum of Understanding on July 5, 2023, to collaborate on local vaccine manufacturing in Saudi Arabia, with Lifera serving as a contract manufacturer utilizing state-of-the-art facilities. The partnership will initially produce seven vaccines from Sanofi's mandatory immunization schedule, aiming to enhance local accessibility and potentially target regional export markets while supporting Saudi Arabia's Vision 2030 goals. The agreement involves technology transfer from Sanofi, leveraging Arabio and Tamer Group's local and regional distribution capabilities, to build national resilience and advance Saudi Arabia's biopharmaceutical sector self-sufficiency.